Abstract
It has long been accepted that high concentrations of glutamate can destroy neurons,and this is the basis of the theory of excitotoxicity during brain injury such as stroke.Glutamate N-methyl- D-aspartate (NMDA)receptor antagonists such as Selfotel,Aptiganel,Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.The failure of these agents has been attributed to poor studies in animal models and to poorly designed clinical trials.We also speculate that NMDA receptor anatagonism may have hindered endogenous mechanisms for neuronal survival and neuroregeneration.It remains to be proven in human stroke whether NMDA receptor antagonism can be neuroprotective.
Keywords: Ischemic Stroke, D-aspartate, glutamate, Aptiganel
Current Molecular Medicine
Title: The Rise and Fall of NMDA Antagonists for Ischemic Stroke
Volume: 4 Issue: 2
Author(s): L. Hoyte, P. A. Barber, A. M. Buchan and M. D. Hill
Affiliation:
Keywords: Ischemic Stroke, D-aspartate, glutamate, Aptiganel
Abstract: It has long been accepted that high concentrations of glutamate can destroy neurons,and this is the basis of the theory of excitotoxicity during brain injury such as stroke.Glutamate N-methyl- D-aspartate (NMDA)receptor antagonists such as Selfotel,Aptiganel,Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.The failure of these agents has been attributed to poor studies in animal models and to poorly designed clinical trials.We also speculate that NMDA receptor anatagonism may have hindered endogenous mechanisms for neuronal survival and neuroregeneration.It remains to be proven in human stroke whether NMDA receptor antagonism can be neuroprotective.
Export Options
About this article
Cite this article as:
Hoyte L., Barber A. P., Buchan M. A. and Hill D. M., The Rise and Fall of NMDA Antagonists for Ischemic Stroke, Current Molecular Medicine 2004; 4 (2) . https://dx.doi.org/10.2174/1566524043479248
DOI https://dx.doi.org/10.2174/1566524043479248 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Disrupted Functional Connectivity Related to Differential Degeneration of the Cingulum Bundle in Mild Cognitive Impairment Patients
Current Alzheimer Research Carotenoids of Microalgae Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry The First Approved Agent in the Glitazar’s Class: Saroglitazar
Current Drug Targets Anesthetics Act in Quantum Channels in Brain Microtubules to Prevent Consciousness
Current Topics in Medicinal Chemistry NMDA/NR2B Selective Antagonists in the Treatment of Ischemic Brain Injury
Current Drug Targets - CNS & Neurological Disorders Neurolological Disorders and Neuroprotection After Heart Surgery
Recent Patents on CNS Drug Discovery (Discontinued) Anorexia of Aging
Current Nutrition & Food Science Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design Autism: Pathophysiology and Promising Herbal Remedies
Current Pharmaceutical Design Targeting the NMDA Receptor for Fear-Related Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Ocular Toxocariasis: New Diagnostic and Therapeutic Perspectives
Recent Patents on Anti-Infective Drug Discovery 5-Lipoxygenase in the Central Nervous System: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents The Akt-mTOR Pathway in Down’s Syndrome: The Potential Use of Rapamycin/Rapalogs for Treating Cognitive Deficits
CNS & Neurological Disorders - Drug Targets A New Approach for Skin-Derived Precursors to Ameliorate Skin Photodamage Through Activation of Nrf2 Signaling Pathway
Current Signal Transduction Therapy Targeting Sarcomas: Novel Biological Agents and Future Perspectives
Current Drug Targets New Indications for Corticosteroids in Intensive Care Units
Current Drug Targets Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design